Marinus Pharmaceuticals, Inc. ( NASDAQ:MRNS ) just released its latest first-quarter report and things are not looking...
Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of 0% and 10.81%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
RADNOR, Pa., May 08, 2024--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and financial results for the first quarter ended March 31, 2024.